Skip to main content
Search
Home    /    Insights & Resources

Insights & Resources

Start exploring insights from across the industries we serve, featuring the latest industry trends, compliance alerts, tax and accounting news and much more.

Life sciences companies often overlook SOX in IPO prep. Discover how early action and targeted strategies can strengthen investor confidence.
J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.
The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.
Weaver’s overview of the SEC’s 2025 examination priorities describe practices by investment advisers and others that may come under SEC review.
The home health and hospice sectors are facing significant challenges with personal care emerging as the key sector for mitigating risk.
Updates to Form PF were designed to assess systemic risk and bolster regulatory oversight in the growing hedge fund industry. Find out more.
The SEC proposed new regulations to establish disclosure requirements for funds and advisers that market themselves as having an ESG focus.
Under the Investment Advisers Act of 1940, the SEC proposed a rule that would bring new audit and reporting requirements as well as prohibit certain actions.
Featured in Hart Energy, Weaver’s ESG Service Leader, Greg Englert, shares his insight around the growing expectations for transparency in ESG reporting and how energy companies can begin planning their reporting now.